ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

ADMA Biologics, Inc.NASDAQ: ADMA

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $124.4M rose 2.0% year over year, behind the +8.0% change in trailing-twelve-month revenue. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $534.79M (+4.8%) for the fiscal year ending Dec 2026, a slowdown from the +19.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$124.4M+8.6% QoQ
Last fiscal yearDec 2025
$510.17M+19.6% YoY
LTMJun 2026
$512.28M+8.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%+2.9%+0.9 pp
1 year+19.6%+4.8%-14.8 pp
3-year CAGR+49.0%+11.0%-38.0 pp
5-year CAGR+11.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
510.17M USD
Year-over-year change
+19.6%
4-year CAGR
+58.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +8.0% is the 3rd highest of 4, against a peer median of +52.3%.
  • Over three fiscal years its annual growth of +49.0% compares with a peer median of -11.4%.
ADMA Competitors
Revenue for ADMA and competitors
Company Period LTM YoY 3-year CAGR
GRFSGrifols, S.A.LTM Jun 2026€7.43B EUR-0.2%+6.0%
ADMAADMA Biologics, Inc.LTM Jun 2026$512.28M USD+8.0%+49.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.45M USD+2889.9%-28.8%
IVVDInvivyd, Inc.LTM Mar 2026$55.87M USD+52.3%—
Peer median (excluding ADMA) —+52.3%-11.4%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.